See more : Northern Star Investment Corp. (NSTB-WT) Income Statement Analysis – Financial Results
Complete financial analysis of Summit Therapeutics Inc. (SMMT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Summit Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Television Broadcasts Limited (TVBCF) Income Statement Analysis – Financial Results
- Leaf Resources Limited (LER.AX) Income Statement Analysis – Financial Results
- Amata Summit Growth Freehold and Leasehold Real Estate Investment Trust (AMATAR.BK) Income Statement Analysis – Financial Results
- Shanghai Electric Group Company Limited (SIELY) Income Statement Analysis – Financial Results
- Tsubakimoto Chain Co. (6371.T) Income Statement Analysis – Financial Results
Summit Therapeutics Inc. (SMMT)
About Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 704.30K | 1.81M | 860.00K | 632.02K | 56.41M | 35.98M | 2.88M | 0.00 | 2.27M | 2.27M | 2.87M | 2.77M | 1.21M | 301.95K | 266.64K | 6.03M | 2.03M | 947.89K | 212.76K | 1.82K |
| Cost of Revenue | 2.05M | 2.51M | 0.00 | 0.00 | 155.40K | 24.92K | 97.67K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01M | 0.00 | 0.00 | 5.77K | 2.51M | 596.30K | 415.93K | 169.46K | 1.82K |
| Gross Profit | -2.05M | -1.81M | 1.81M | 860.00K | 476.62K | 56.39M | 35.88M | 2.88M | 0.00 | 2.27M | 2.27M | 2.87M | 1.77M | 1.21M | 301.95K | 260.87K | 3.51M | 1.43M | 531.96K | 43.31K | 0.00 |
| Gross Profit Ratio | 0.00% | -256.95% | 100.00% | 100.00% | 75.41% | 99.96% | 99.73% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 63.68% | 100.00% | 100.00% | 97.84% | 58.28% | 70.60% | 56.12% | 20.35% | 0.00% |
| Research & Development | 59.47M | 52.00M | 85.35M | 53.27M | 32.71M | 51.38M | 41.01M | 23.69M | 23.94M | 15.64M | 10.83M | 5.72M | 4.78M | 3.66M | 3.68M | 7.38M | 15.34M | 5.79M | 1.83M | 504.60K | 0.00 |
| General & Administrative | 30.27M | 26.70M | 23.61M | 19.23M | 7.24M | 16.19M | 16.98M | 10.35M | 7.45M | 6.80M | 3.24M | 2.77M | 2.31M | 2.68M | 3.83M | 3.91M | 5.14M | 863.07K | 1.79M | 75.31K | 43.79K |
| Selling & Marketing | -2.05M | 0.00 | 0.00 | 0.00 | 2.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 372.24K | 1.12M | 2.17M | 1.00M | 0.00 | 0.00 | 0.00 |
| SG&A | 28.22M | 26.70M | 23.61M | 19.23M | 9.30M | 16.19M | 16.98M | 10.35M | 7.45M | 6.80M | 3.24M | 2.77M | 2.31M | 2.68M | 4.20M | 5.03M | 7.31M | 1.86M | 1.79M | 75.31K | 43.79K |
| Other Expenses | 0.00 | -14.42M | -20.97M | -19.31M | 0.00 | -19.88M | -3.86M | -1.95M | -3.14M | -682.90K | -682.90K | 18.95K | 339.19K | -10.32M | 3.48M | 2.97M | 2.70M | 2.37M | 119.60K | 0.00 | -1.82K |
| Operating Expenses | 87.69M | 64.28M | 88.00M | 53.19M | 42.00M | 47.69M | 54.13M | 33.94M | 29.45M | 19.29M | 13.33M | 8.51M | 7.45M | 5.55M | 9.49M | 15.43M | 26.92M | 10.03M | 3.74M | 579.92K | 43.79K |
| Cost & Expenses | 89.74M | 64.28M | 88.00M | 53.19M | 43.40M | 47.69M | 54.13M | 33.94M | 29.45M | 19.29M | 13.33M | 8.51M | 7.45M | 5.55M | 9.49M | 15.43M | 29.43M | 10.62M | 4.16M | 749.37K | 45.61K |
| Interest Income | 10.40M | 1.51M | 178.95K | 4.00K | 4.34K | 3.66M | 4.38M | 10.00K | 30.00K | 0.00 | 14.85K | 17.37K | 10.99K | 26.90K | 12.78K | 430.95K | 1.54M | 1.72M | 1.04M | 404.81K | 1.82K |
| Interest Expense | 16.46M | 4.40M | 281.00K | 255.00K | 32.52K | 556.10K | 1.65M | 1.08M | 0.00 | 448.00K | 0.00 | 0.00 | 4.71K | 6.33K | 107.04K | 116.74K | 75.56K | 11.77K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 90.74M | 2.51M | 2.46M | 2.00M | 1.39M | 1.49M | 348.21K | 72.50K | 68.36K | 49.72K | 42.89K | 146.89K | 295.22K | 710.54K | 3.78M | 2.74M | 3.28M | 737.53K | 240.99K | 9.41K | 1.82K |
| EBITDA | 1.00M | -52.63M | -62.74M | -37.13M | -16.80M | 11.66M | -32.19M | -30.98M | -20.30M | -12.20M | -11.02M | -5.48M | -4.41M | -8.65M | -5.41M | -16.03M | -18.58M | -6.13M | -2.97M | -527.20K | -41.96K |
| EBITDA Ratio | 0.00% | -8,633.17% | -4,764.29% | -5,985.47% | -6,546.15% | 24.59% | -37.31% | -1,075.82% | 0.00% | -854.30% | -486.04% | -191.35% | -157.79% | -298.82% | -1,786.78% | -4,499.47% | -308.42% | -302.42% | -203.69% | -57.52% | -2,300.00% |
| Operating Income | -89.74M | -72.09M | -86.19M | -53.19M | -42.76M | 12.38M | -18.25M | -31.07M | -28.73M | -19.15M | -11.07M | -7.23M | -4.71M | -9.38M | -9.20M | -19.20M | -23.40M | -8.60M | -3.21M | -536.61K | -43.79K |
| Operating Income Ratio | 0.00% | -10,235.63% | -4,764.29% | -6,185.23% | -6,766.39% | 21.95% | -50.73% | -1,078.69% | 0.00% | -844.40% | -487.93% | -252.32% | -170.09% | -777.06% | -3,047.63% | -7,198.94% | -388.45% | -423.79% | -338.91% | -252.21% | -2,400.00% |
| Total Other Income/Expenses | -526.14M | -19.15M | -24.87M | -14.01M | -1.04M | -3.30M | 1.91M | -854.00K | 5.54M | -427.00K | 14.85K | 17.37K | 6.28K | 20.57K | -94.26K | 314.20K | 1.47M | 1.71M | 1.04M | 404.81K | 1.82K |
| Income Before Tax | -615.87M | -78.78M | -88.60M | -52.91M | -28.41M | 6.60M | -15.42M | -32.13M | -28.69M | -19.07M | -11.05M | -7.21M | -4.71M | -9.36M | -9.30M | -18.88M | -21.94M | -6.88M | -2.17M | -131.80K | -41.96K |
| Income Before Tax Ratio | 0.00% | -11,185.94% | -4,897.84% | -6,152.33% | -4,494.86% | 11.70% | -42.85% | -1,115.76% | 0.00% | -841.02% | -487.27% | -251.71% | -169.86% | -775.36% | -3,078.84% | -7,081.10% | -364.13% | -339.36% | -229.12% | -61.95% | -2,300.00% |
| Income Tax Expense | -946.00K | -4.40M | -2.46M | -213.00K | -4.52M | -3.27M | -5.32M | -5.42M | -4.36M | -1.95M | -1.00M | -538.61K | -477.37K | -1.94M | -594.31K | -2.52M | -1.81M | -959.18K | -278.48K | -45.19K | -1.82K |
| Net Income | -614.93M | -74.38M | -86.15M | -52.70M | -23.88M | 9.87M | -10.09M | -26.71M | -24.34M | -17.12M | -10.05M | -6.67M | -4.23M | -7.42M | -8.66M | -32.29M | -20.13M | -5.92M | -1.89M | -86.61K | -41.96K |
| Net Income Ratio | 0.00% | -10,561.06% | -4,762.13% | -6,127.56% | -3,779.08% | 17.50% | -28.05% | -927.56% | 0.00% | -754.85% | -443.13% | -232.91% | -152.63% | -614.68% | -2,867.20% | -12,109.76% | -334.06% | -292.07% | -199.74% | -40.71% | -2,300.00% |
| EPS | -0.99 | -0.38 | -0.93 | -0.76 | -0.15 | 0.11 | -0.16 | -0.43 | -0.41 | -0.43 | -2.08 | -0.42 | -0.02 | -0.04 | -0.13 | -0.60 | -0.42 | -0.16 | -0.06 | 0.00 | 0.00 |
| EPS Diluted | -0.99 | -0.38 | -0.93 | -0.76 | -0.15 | 0.11 | -0.15 | -0.43 | -0.41 | -0.43 | -2.08 | -0.42 | -0.02 | -0.04 | -0.13 | -0.60 | -0.42 | -0.16 | -0.06 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 619.65M | 193.34M | 92.24M | 69.52M | 164.15M | 86.14M | 65.03M | 61.55M | 59.10M | 39.60M | 4.83M | 15.81M | 177.88M | 166.29M | 67.01M | 53.39M | 47.90M | 36.42M | 31.31M | 23.47M | 19.02M |
| Weighted Avg Shares Out (Dil) | 619.65M | 193.34M | 92.24M | 69.52M | 164.15M | 86.14M | 65.43M | 61.55M | 59.10M | 39.60M | 4.83M | 15.81M | 177.88M | 166.29M | 67.01M | 53.39M | 47.90M | 36.42M | 31.31M | 23.47M | 19.02M |
Summit Therapeutics' stock pops as lung-cancer treatment beats Merck blockbuster in late-stage trial
Shares of Summit Therapeutics Inc. jumped more than 30% premarket on Monday after the biotech company released late-stage trial data showing that its experimental lung-cancer treatment topped Merck's blockbuster Keytruda.
Biotech Stocks: Lung Cancer Treatment Outflanks Merck's Keytruda
Summit shares jumped Monday after positive late-stage indications vs. Merck's Keytruda.
Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half
Sunday, Summit Therapeutics Inc. SMMT released data from the primary analysis of the Phase 3 HARMONi-2 trial of ivonescimab conducted in China, sponsored by collaboration partner Akeso, Inc.
Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced data from the primary analysis of the Phase III HARMONi-2 trial featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was presented this morning...
Two Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive NSCLC to Be Presented at WCLC 2024
First Release of Phase III Head-to-Head Clinical Study Data of Ivonescimab versus Pembrolizumab in NSCLC Ivonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab in a Randomized Phase III Clinical Trial in NSCLC HONG KONG , Aug....
Summit Therapeutics Inc. (SMMT) Q2 2024 Earnings Call Transcript
Summit Therapeutics Inc. (NASDAQ:SMMT ) Q2 2024 Results Conference Call August 6, 2024 9:00 AM ET Company Participants Dave Gancarz - Chief Business and Strategy Officer Bob Duggan - Chairman and Chief Executive Officer Maky Zanganeh - Chief Executive Officer,...
3 Small-Cap Stocks That Could Outperform the “Magnificent 7”
Recent headlines have highlighted the shift many investors are making from large-cap to small cap stocks.
Summit Therapeutics May Have Further Upside From Here
Summit Therapeutics to release second-quarter earnings and operational update on 6 August. Analysts are bullish on Phase 3 trial results for Ivonescimab in September, with a potential de-risking of the drug's profile. The company boosted its balance sheet with a...
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 330,000 shares of common stock. Awards were made to six new...
3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street
These three stocks have soared between 179% and 220% so far this year. Wall Street thinks they can all jump at least 20% over the next 12 months.
Source: https://incomestatements.info
Category: Stock Reports